Key result
Novel risk score stratifies VTE risk in lung cancer using hemoglobin, metastasis, histology, and smoking.
Why the study?
Venous thromboembolism is a common and potentially fatal complication in patients with lung cancer, motivating the development and validation of a risk score for early prediction.
Can a novel clinical risk score predict venous thromboembolism in hospitalized patients with lung cancer?
Cohort (n=401)
Yes
Can a novel clinical risk score predict venous thromboembolism in hospitalized patients with lung cancer?
Effect estimate: c statistic 0.703
A novel 4-item risk score provides moderate predictive value for venous thromboembolism in hospitalized lung cancer patients, though prospective validation is needed.
May support VTE risk stratification in lung cancer inpatients; leaves open need for prospective validation before adoption.
<ns3:p> <ns3:bold>Background:</ns3:bold> Venous thromboembolism (VTE) is a common and potentially fatal complication in patients with lung cancer. This study aimed to develop and validate a risk score for early prediction of VTE in these patients. </ns3:p> <ns3:p> <ns3:bold>Methods:</ns3:bold> Four hundred and one patients with lung cancer from three pulmonology departments hospitalized between January 2011 and December 2021 were retrospectively assessed. The population was divided into two groups: a Development Group (182 patients) and a validation group (199 patients). In the development group, the risk score system was developed, via univariate and multivariate analyses, based on demographic and clinicopathological variables; it was then validated in the validation group. </ns3:p> <ns3:p> <ns3:bold>Results:</ns3:bold> The incidence of VTE was 26.8% in the development group. It was 25.8%, and 27.6% in the internal and external validation groups, respectively. Hemoglobin level <10g/l, metastasis, histological type poorly or undifferentiated non-small cell carcinoma, and active smoking were the items of the risk score system. This score allowed proper stratification of patients with either high or low risk of VTE in the development group (c statistic =0.703). The patients in the development group were classified into 3 risk groups: low risk (scores 0-1), moderate risk (scores 2-3), and high risk (scores 4-5). When validated in the validation group, there was a moderate loss of predictive power of the score (c statistic=0.641), but the categorization of the patients by the score remained clinically useful. </ns3:p> <ns3:p> <ns3:bold>Conclusions:</ns3:bold> This risk score requires prospective validation studies on a nationwide scale in order to use it as a valid tool for the prevention of VTE in lung cancer. </ns3:p>
No takes yet. Share an insight, caveat, or question.
Rouis et al. (2023) conducted a cohort in lung cancer (n=401). VTE risk score was evaluated on Venous thromboembolism (VTE) (c statistic 0.703). A novel risk score comprising hemoglobin <10g/l, metastasis, histology, and active smoking stratified VTE risk in lung cancer patients (c-statistic 0.703 in development, 0.641 in validation).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: